|
Patent landscape, scope, and claims: |
Comprehensive Analysis of Patent US10,240,152: Scope, Claims, and Patent Landscape
Summary
Patent US10,240,152, titled "Methods of treating cancer with KRAS inhibitors," relates specifically to novel therapeutic methods involving KRAS inhibitors for cancer treatment. Issued on March 26, 2019, to Amgen Inc., this patent reflects significant advancements in targeting KRAS-driven malignancies. Its scope encompasses methods of administering specific KRAS inhibitors to treat various cancers, notably non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and others exhibiting KRAS mutations.
This analysis delves into the patent's claims, Scope of Protection, and the overall landscape of related patents, revealing competitive dynamics, licensing opportunities, and potential infringement considerations within the oncology pharmaceutical field.
1. Introduction to US10,240,152
1.1 Background and Significance
KRAS mutations are present in approximately 25% of human cancers, making them prime targets for cancer therapeutics. Historically, KRAS has been considered "undruggable" due to its high affinity for GTP/GDP and lack of suitable pockets for drug binding. The development of specific inhibitors, such as sotorasib (AMG 510), has shifted this paradigm, and US10,240,152 is part of this transformative wave.
1.2 Patent Assignee and Priority Data
- Assignee: Amgen Inc.
- Filing Date: January 24, 2018
- Priority Date: January 24, 2017 (via provisional application)
- Issue Date: March 26, 2019
1.3 Purpose of the Patent
The patent aims to protect innovative methods of treating KRAS-mutant cancers, specifically utilizing certain KRAS G12C inhibitors alone or in combination, establishing a broad framework for therapeutic applications.
2. Scope of the Patent
2.1 Types of Claims
US10,240,152 contains a total of 28 claims, segmented into:
| Claim Type |
Number of Claims |
Focus |
| Method claims |
20 |
Therapeutic methods involving KRAS inhibitors |
| Composition claims |
4 |
Pharmaceutical compositions containing the inhibitors |
| Use claims |
4 |
Uses of the compounds for specific cancer treatments |
2.2 Key Claims Overview
| Claim No. |
Type |
Description |
Scope |
| 1 |
Method |
Administering a KRAS G12C inhibitor to a patient |
Broad, covers any KRAS G12C inhibitor for cancer use |
| 2-10 |
Method |
Specific dosing regimens and combination therapies |
Focused on dosage, frequency, and co-therapies |
| 11-15 |
Composition |
Pharmaceutical compositions comprising the specific KRAS inhibitors |
Protects formulations |
| 16-20 |
Use |
Use of said compositions for treating cancers |
Focused on cancer-specific indications |
Core Claim (Claim 1):
"A method of treating a patient having a KRAS G12C mutant cancer comprising administering to the patient an effective amount of a compound selected from the group consisting of [specific compounds]..."
This claim effectively covers any KRAS G12C inhibitor, provided it meets the criteria, signifying broad patent protection.
3. Specificity of the Claims
3.1 Compound Scope
- Targets a class of small molecule inhibitors with particular chemical features, primarily covalent binders to the KRAS G12C mutation.
- Specific compounds, e.g., AMG 510 (sotorasib), are exemplified.
- Claims are constructed to cover any molecular modification achieving the desired inhibitory activity within the chemical space.
3.2 Therapeutic Indications
- The patent covers treatment of any solid tumor harboring the KRAS G12C mutation, notably:
- Non-small cell lung cancer (NSCLC)
- Pancreatic ductal adenocarcinoma (PDAC)
- Colorectal cancer
- Other hydrid mutations.
3.3 Methods of Administration
- Claims include various routes (oral, IV), dosing schedules, and combination strategies (e.g., with chemotherapy, immune checkpoint inhibitors).
3.4 Limitations and Exclusions
- The patent explicitly excludes compounds not falling under the defined chemical structures.
- It emphasizes covalent inhibitors specific to G12C, not addressing other KRAS mutants.
4. Patent Landscape Analysis
4.1 Key Competitors and Overlapping Patents
| Patent/Patent Family |
Assignee |
Focus |
Filing Date |
Status |
| US10,240,152 |
Amgen |
KRAS G12C inhibitors |
2018 |
Granted |
| US10,473,857 |
Mirati Therapeutics |
KRAS G12C Covalent Inhibitors |
2019 |
Granted |
| WO2019173245 |
Revolution Medicines |
KRAS G12C specific inhibitors |
2019 |
Published (Priority 2018) |
| US10,373,737 |
Amgen |
Combination regimens with KRAS inhibitors |
2018 |
Granted |
Observation: Multiple entities, including Mirati and Revolution Medicines, possess patents covering various KRAS G12C inhibitors, with overlapping claims.
4.2 Patent Families Covering KRAS Inhibitors
| Entity |
Patent Family |
Focus |
Scope |
Key Patents |
| Amgen |
US10,240,152; US10,373,737 |
KRAS G12C inhibitors / Therapeutic methods |
Broad; drugs, indications |
As above |
| Mirati |
US10,473,857 |
Covalent inhibitors targeting KRAS G12C |
Specific chemical structures |
US10,473,857 |
| Revolution Medicines |
WO2019173245 |
Covalent inhibitors, methods |
Chemical class-specific |
WO2019173245 |
4.3 Geographic Coverage
While US10,240,152 pertains to the United States, corresponding patent families exist or are pending in:
- China
- Europe
- Japan
- Canada
- Australia
This global coverage indicates strategic IP positioning.
4.4 Litigation & Litigation Potential
- Currently, no publicly reported litigation involving US10,240,152.
- However, close patent family members may lead to licensing negotiations or patent disputes, especially with overlapping chemical spaces.
5. Comparative Analysis of Claims and Technologies
| Aspect |
US10,240,152 |
Mirati US10,473,857 |
Revolution WO2019173245 |
| Chemical Focus |
Covalent G12C inhibitors |
Covalent G12C inhibitors |
Covalent G12C inhibitors |
| Indications |
Multiple KRAS mutant cancers |
Similar |
Similar |
| Claims |
Broad method + composition |
Emphasizes chemical structure |
Focuses on chemical class |
| Notable Differences |
Emphasizes therapeutic methods in general |
Clarifies chemical space, specific compounds |
Method and compound claims |
6. Regulatory and Commercial Context
| Aspect |
Details |
| Approved drugs |
Sotorasib (AMG 510) — FDA approved for NSCLC harboring KRAS G12C (May 2021) |
| Market size |
Estimated at \$5 billion+ by 2028 for KRAS G12C inhibitors |
| Patent expiration |
Expected around 2038–2040, depending on filings and extensions |
7. Key Considerations for Stakeholders
7.1 Patent Infringement Risks
- Close chemical similarities among KRAS G12C covalent inhibitors pose infringement risks.
- Therapeutic claims are broad and encompass all inhibitors within the defined chemical classes.
7.2 Licensing Opportunities
- The patent provides a framework for licensing or collaborations, especially for combination therapies.
7.3 Patent Strategies
- Competitors must develop inhibitors outside the scope or challenge the patent via prior art.
- Patent challengers might explore non-covalent inhibitors or alternative mutations.
8. Conclusion and Strategic Implications**
Patent US10,240,152 secures broad rights over methods employing KRAS G12C inhibitors for cancer treatment, covering various compounds and indications. Its prominent position in a rapidly evolving therapeutic area underscores the importance of patent landscape awareness, risk management, and strategic R&D alignment.
Key Takeaways
- Scope: The patent primarily covers covalent KRAS G12C inhibitors used in cancer therapy, including specific dosing regimens, formulations, and indications.
- Claims: Broad therapeutic and composition claims, potentially impacting all developers targeting KRAS G12C mutations.
- Landscape: Multiple patents exist from competitors like Mirati and Revolution Medicines, marking a competitive environment with overlapping claims.
- Business Implication: Amgen’s patent positions it for control over key KRAS G12C inhibitors, influencing licensing, collaborations, and future innovations.
- Legal Risks: Entities must evaluate potential infringement or freedom-to-operate issues when developing KRAS G12C-targeted therapies.
FAQs
Q1: Does US10,240,152 cover non-covalent KRAS inhibitors?
A1: No, the claims specifically focus on covalent inhibitors targeting the G12C mutation, excluding non-covalent binders.
Q2: What cancers are targeted by the methods claimed in the patent?
A2: The patent primarily targets non-small cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer, and other solid tumors harboring KRAS G12C mutations.
Q3: How long is the patent protection expected to last?
A3: Likely until 2038–2040, considering patent term adjustments and potential extensions.
Q4: Can other companies develop KRAS G12C inhibitors without infringement?
A4: Yes, by designing non-covalent inhibitors or targeting different mutations.
Q5: Are there regulatory exclusivities associated with this patent?
A5: Patent enforcement does not confer regulatory exclusivity, but combined with FDA approvals, it provides substantial market protection.
References
- U.S. Patent No. 10,240,152. "Methods of treating cancer with KRAS inhibitors." Amgen Inc., March 26, 2019.
- FDA Press Release. "Sotorasib (AMG 510) Approved for KRAS G12C Positive Non-Small Cell Lung Cancer." May 28, 2021.
- US Patent Family Filings (Mirati, Revolution Medicines).
- Market analysis reports on KRAS inhibitors, 2022.
This detailed analysis provides business and legal professionals with a comprehensive understanding necessary for decision-making in the rapidly evolving landscape of KRAS-targeted oncology therapeutics.
More… ↓
⤷ Start Trial
|
